Teladoc executive sells 9,572 shares in open market

Teladoc Health, Inc. executive Fernando M. Rodrigues, President of BetterHelp, reported an open-market sale of 9,572 shares of common stock at $7.40 per share.

Accepted by SEC EDGAR 06/04/2026 - 04:05 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Teladoc Health, Inc. executive Fernando M. Rodrigues, President of BetterHelp, reported an open-market sale of 9,572 shares of common stock at $7.40 per share. Following this transaction, his directly held common stock position in this account was reduced to 0 shares. The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 3, 2025, indicating the trades were scheduled in advance.

Insider Trade Summary 10b5-1

Net Seller: 9,572 shares

Net Sell 1 txn

Insider Rodrigues Fernando M.

Role President of BetterHelp

Sold 9,572 shs ($71K)

Share of Position Sold 100%

Type	Security	Shares	Price	Value
Sale	Common Stock	9,572	$7.40	$71K

Holdings After Transaction: Common Stock — 0 shares (Direct)

Holdings Before and After: Common Stock, 9,572 to 0 shares (Direct)

Other Insiders: 5 other insiders reported open-market sales of this stock in the 30 days up to this filing.

Footnotes (1)

1. F1. The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan that was adopted by the reporting person on November 3, 2025.

Key Figures

Shares sold: 9,572 shares Sale price: $7.40 per share Shares after transaction: 0 shares +1 more

4 metrics

Shares sold 9,572 shares Common Stock, open-market sale

Sale price $7.40 per share Reported transaction price

Shares after transaction 0 shares Total common shares directly held in this account

Trading plan adoption date November 3, 2025 Rule 10b5-1 trading plan adoption

Key Terms

Rule 10b5-1 trading plan, open-market sale, Form 4, Common Stock

4 terms

Rule 10b5-1 trading plan regulatory

"The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

open-market sale financial

"transaction_action: "open-market sale" for 9,572 shares of Common Stock"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Form 4 regulatory

"The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

Common Stock financial

"security_title: "Common Stock" with 9,572.0000 shares sold"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Teladoc Health (TDOC) report for Fernando M. Rodrigues?

Teladoc Health reported that Fernando M. Rodrigues, President of BetterHelp, sold 9,572 shares of common stock. The shares were sold in an open-market transaction at $7.40 per share, and this reduced his directly held common stock position in this account to zero.

At what price were Fernando M. Rodrigues’ Teladoc Health (TDOC) shares sold?

Fernando M. Rodrigues’ Teladoc Health common shares were sold at an average price of $7.40 per share. This price comes from the Form 4 transaction data describing a single open-market sale of 9,572 shares on the reported transaction date.

How many Teladoc Health (TDOC) shares did Fernando M. Rodrigues hold after this Form 4 sale?

After the reported transaction, Fernando M. Rodrigues held 0 shares of Teladoc Health common stock directly in the account referenced. The Form 4 lists 9,572 shares sold and shows total shares following the transaction as 0.0000 for this holding.

Was the Teladoc Health (TDOC) insider sale by Fernando M. Rodrigues under a Rule 10b5-1 plan?

Yes. The Form 4 footnote states the transaction was effected under a Rule 10b5-1 trading plan. That plan was adopted by Fernando M. Rodrigues on November 3, 2025, meaning the sale was pre-arranged rather than decided at the last minute.

What role does Fernando M. Rodrigues hold at Teladoc Health (TDOC)?

In this filing, Fernando M. Rodrigues is identified as President of BetterHelp, a business within Teladoc Health. His status as an officer requires reporting changes in his Teladoc share ownership on Form 4 when he trades company common stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Rodrigues Fernando M.

(Last) (First) (Middle)

C/O TELADOC HEALTH, INC.,

155 E 44TH ST, SUITE 1700

(Street)

NEW YORK NEW YORK 10017

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Teladoc Health, Inc. [ TDOC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President of BetterHelp

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/03/2026		S(1)		9,572	D	$7.4	0	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan that was adopted by the reporting person on November 3, 2025.

Remarks:

	/s/ Adam C. Vandervoort, Attorney-in-Fact	06/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)